Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
PDXHCI002 Ceritinib
0.01
ALK
RTK
 1.0536 -0.01070
PDXHCI002 Ceritinib
0.031623
ALK
RTK
 0.9841 -0.01097
PDXHCI002 Ceritinib
0.1
ALK
RTK
 0.8249 -0.01606
PDXHCI002 Ceritinib
0.31623
ALK
RTK
 0.5616 0.00577
PDXHCI002 Ceritinib
1.0
ALK
RTK
 -0.1541 0.26739
PDXHCI002 Ceritinib
3.1623
ALK
RTK
 -0.6054 0.72078
PDXHCI002 Ceritinib
10.0
ALK
RTK
 -0.6341 0.73056
PDXHCI002 Neratinib
0.00031623
EGFR/HER2
RTK
 1.0577 0.00306
PDXHCI002 Neratinib
0.001
EGFR/HER2
RTK
 1.0061 -0.00143
PDXHCI002 Neratinib
0.0031623
EGFR/HER2
RTK
 1.0149 -0.00959
PDXHCI002 Neratinib
0.01
EGFR/HER2
RTK
 0.8318 -0.01510
PDXHCI002 Neratinib
0.031623
EGFR/HER2
RTK
 0.6460 -0.00351
PDXHCI002 Neratinib
0.1
EGFR/HER2
RTK
 0.5417 -0.01033
PDXHCI002 Neratinib
0.31623
EGFR/HER2
RTK
 0.3928 0.01351
PDXHCI002 Neratinib
1.0
EGFR/HER2
RTK
 0.1846 0.05265
PDXHCI002 Neratinib
3.1623
EGFR/HER2
RTK
 -0.1614 0.33142
PDXHCI002 Tivantinib
0.001
MET
RTK
 1.0240 0.00437
PDXHCI002 Tivantinib
0.0031623
MET
RTK
 1.0776 0.00206
PDXHCI002 Tivantinib
0.01
MET
RTK
 1.0723 0.00111
PDXHCI002 Tivantinib
0.031623
MET
RTK
 1.0374 0.01073
PDXHCI002 Tivantinib
0.1
MET
RTK
 0.9277 0.02896
PDXHCI002 Tivantinib
0.31623
MET
RTK
 0.2461 0.23959
PDXHCI002 Tivantinib
1.0
MET
RTK
 -0.3731 0.60360
PDXHCI002 Tivantinib
3.1623
MET
RTK
 -0.4868 0.71069
PDXHCI002 Tivantinib
10.0
MET
RTK
 -0.4819 0.70680